KRAS and neoplasm: Once KRAS mutations occur, the hydrolysis of GTP is disrupted and/or nucleotide exchange is enhanced, leading to accumulation of KRAS in the active state and contributing to constitutive stimulation of downstream signaling pathways, thereby promoting tumor cell proliferation and survival.